Sugi Predict

Sugi Predict / Compounds / SCHEMBL3200870

SCHEMBL3200870

SCHEMBL3200870

CC(=O)c1ccc(NC(=O)Nc2cc(F)cc(CN3CCN(C(=O)O)CC3)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PRKAA2 P54646 10/20 0.47
▸ FAAH O00519 5/20 0.43
▸ NPC1 O15118 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ ACKR3 P25106 1/20 0.40
▸ PLK4 O00444 1/20 0.40
▸ PAK4 O96013 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ TBK1 Q9UHD2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL402841 0.91 PRKAA2 (0.47) PRKAA2FAAHNPC1TP53RAB9A
SCHEMBL401983 0.89 ALDH1A1 (0.45) PRKAA2POLB
SCHEMBL3209186 0.88 FAAH (0.44) PRKAA2FAAHNPC1TP53POLB
SCHEMBL3201236 0.86 FAAH (0.56) PRKAA2FAAHNPC1TP53POLB
SCHEMBL3210131 0.85 FAAH (0.43) PRKAA2FAAHPLK4PAK4NTRK1
SCHEMBL3214080 0.85 PRKAA2 (0.46) PRKAA2FAAHNPC1TP53POLB
SCHEMBL3207863 0.84 FAAH (0.42) PRKAA2FAAH
SCHEMBL398292 0.82 MAP4K4 (0.45) PRKAA2FAAHPOLBPLK4PAK4
SCHEMBL3189494 0.81 FAAH (0.56) FAAH
SCHEMBL398486 0.79 KDR (0.43) PRKAA2FAAHPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 PRKAA2 2151/4885FAAH 4384/4885NPC1 4481/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 PRKAA2 1051/4885FAAH 4811/4885NPC1 4691/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 PRKAA2 658/4885FAAH 4661/4885NPC1 4804/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 PRKAA2 1051/4885FAAH 4811/4885NPC1 4691/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 PRKAA2 886/4885FAAH 3155/4885NPC1 4826/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 PRKAA2 1051/4885FAAH 4811/4885NPC1 4691/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PRKAA2 1298/4885FAAH 4697/4885NPC1 4608/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 PRKAA2 886/4885FAAH 3155/4885NPC1 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.